Figure 9. GSEA analysis based on the risk value. (A) The significant enrichment of the top 5 GO terms in the high-risk group and the top 5 immune-related GO terms in the low-risk group. (B) The significant enrichment of the top 5 pathways in the high-risk group and the top 5 immune-related pathways in the low-risk group.